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Introduction: Preclinical studies have suggested that the oral anti-
fungal agent itraconazole specifically inhibits proliferation, migra-
tion, and tube formation of endothelial cells. Itraconazole has potent 
antiangiogenic activity and enhances the efficacy of cytotoxic che-
motherapy in multiple primary xenograft lung cancer models. On 
the basis of these data, we performed an exploratory clinical study, 
assessing the efficacy of itraconazole with cytotoxic chemotherapy in 
the treatment of patients with advanced lung cancer.
Methods: The study enrolled patients with progressive nonsqua-
mous non–small-cell lung cancer after one prior cytotoxic therapy for 
metastatic disease, randomized 2:1 to intravenous administration of 
pemetrexed 500 mg/m2 on day 1, with or without itraconazole 200 mg 
orally daily, on a 21-day cycle. Outcome measures included percent 
progression-free at 3 months, progression-free survival, overall sur-
vival, and observed toxicity.
Results: A total of 23 patients were enrolled; the study was stopped 
early because of increasing use of pemetrexed in the first-line setting. 
At 3 months, 67% of the patients on itraconazole plus pemetrexed 
were progression-free versus 29% on the control arm of pemetrexed 
alone (p = 0.11). Median progression-free survivals were 5.5 months 
(itraconazole) versus 2.8 months (control) (hazard ratio = 0.399, p = 
0.089). Overall survival was longer in patients receiving itraconazole 
(median 32 months) versus control (8 months) (hazard ratio = 0.194, 
p = 0.012). There were no evident differences in toxicity between the 
study arms.
Conclusion: Itraconazole is well tolerated in combination with peme-
trexed. Consistent with our preclinical data, daily itraconazole admin-
istration is associated with trends suggestive of improved disease 
control in patients receiving chemotherapy for advanced lung cancer.
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(J Thorac Oncol. 2013;8: 619-623)
Lung cancer is the leading cause of cancer-related deaths in the United States, and is responsible for more deaths than 
colon, breast, and prostate cancers combined.1,2 More effec-
tive treatments for this disease are critically needed. Solid 
tumor growth and progression is dependent on tumor-asso-
ciated angiogenesis.3 Tumor expression and circulating levels 
of angiogenic factors have been correlated with aggressive 
tumor growth, predilection for metastasis, and prognosis in a 
wide array of solid tumors, including non–small-cell lung can-
cer (NSCLC).4–6 The only currently approved antiangiogenic 
therapy for lung cancer is the monoclonal antibody, bevaci-
zumab, directed against the vascular endothelial growth fac-
tor (VEGF). A landmark phase III clinical study, the Eastern 
Cooperative Oncology Group (ECOG) 4599, randomized 878 
patients with advanced nonsquamous NSCLC to a standard 
chemotherapy doublet with or without bevacizumab.7 This 
study demonstrated a statistically significant improvement in 
both progression-free survival and overall survival in favor of 
the bevacizumab-containing arm.
Although the ECOG 4599 study indicated the potential 
for antiangiogenic therapy to improve outcome in solid 
tumor patients, there were major limitations in these data 
as well. First, the absolute improvements in progression-
free and overall survival were modest (1.7 and 2 months, 
respectively). Second, there were significant toxicities 
attributable to bevacizumab, with 15 treatment-related deaths 
on the bevacizumab arm (as opposed to 2 on the control 
arm; p = 0.001), including multiple fatal hemoptyses. The 
rates of hypertension, proteinuria, bleeding, neutropenia, 
febrile neutropenia, thrombocytopenia, hyponatremia, rash, 
and headache were significantly higher for bevacizumab (p 
< 0.05 for each). Third, the financial cost of bevacizumab, 
given the limited efficacy and significant toxicity, was seen 
by many as excessive, with an incremental cost-utility ratio 
compared with chemotherapy alone of more than $500,000 
per quality-adjusted year of life.8 A final concern came from 
a confirmatory trial—the AVAstin in Lung (AVAiL) study, 
which enrolled 1043 patients randomized to cisplatin and 
gemcitabine with or without bevacizumab.9 This study failed 
to demonstrate a statistically significant difference in survival.9 
In summary, although evidence is strong that angiogenesis is 
critical to tumor growth, less toxic, less cost-prohibitive, and 
more effective therapies are needed.
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We performed a high throughput screen for agents with 
previously unsuspected antiangiogenic activity, using differ-
ential inhibition of endothelial cell proliferation as an initial 
assay.10 Itraconazole was found to be among the most potent 
and selective inhibitors of endothelial cell proliferation, with 
IC
50
 of 0.16 M for human umbilical vein endothelial cells, 
and minimal if any, antiproliferative effects against multiple 
nonendothelial controls (IC
50
s > 100 M). None of the several 
related antifungal agents had similar activity.
Subsequently, we conducted a series of preclinical anal-
yses of itraconazole, using both in vitro and in vivo model sys-
tems.11 Itraconazole inhibited endothelial cell proliferation in 
response to known angiogenic drivers, including both VEGF 
and fibroblast growth factor (FGF), and inhibited phosphory-
lation of the primary angiogenic receptors for these factors. 
Itraconazole led to a dose-dependent suppression of VEGF- 
and FGF-mediated endothelial cell migration and VEGF- and 
FGF-mediated endothelial tube formation. Oral itraconazole 
administration to animals bearing primary xenograft NSCLCs 
resulted in tumor growth inhibition similar to that achieved 
with cisplatin, and in combination with cisplatin resulted in an 
even more marked suppression of tumor growth. Use of itra-
conazole in vivo was associated with tumor hypoxia, as shown 
by induction of tumor-specific expression of hypoxia induc-
ible factor-1α (HIF-1α), as well as decreased tumor microves-
sel density, and tumor vascular area.11
Taken together, these data support the hypothesis that 
itraconazole may have substantial promise as a novel antian-
giogenic agent. In contrast to bevacizumab, itraconazole is an 
inexpensive oral agent, off patent, and currently available in 
a generic formulation. Itraconazole has been safely admin-
istered to thousands of patients, including patients receiving 
high-dosage cytotoxic therapy for allogeneic bone marrow 
transplantation.12
In this study, the first to evaluate the potential anticancer 
activity of itraconazole in conjunction with standard chemo-
therapy for patients with lung cancer, we initiated a random-
ized study of standard-dosage pemetrexed as second-line 
therapy for nonsquamous NSCLC, given with or without itra-
conazole at a standard antifungal dosage of 200 mg daily. In 
the 571 patient phase III trial that supported the U.S. Food and 
Drug Administration registration of pemetrexed in the sec-
ond-line setting for metastatic NSCLC, a 3-month event-free 
survival was approximately 40%, median progression-free 
survival (PFS) was 2.9 months, and median overall survival 
was 8.3 months.13 We hypothesized that the antiangiogenic 
activity of itraconazole might lead to improved disease control 
with minimal additional toxicity in patients with recurrent and 
progressive nonsquamous NSCLC.
MATERIALS AND METHODS
Patient Population
Eligible candidates for this study (NCT00769600) were 
adults with histologically or cytologically confirmed nonsqua-
mous NSCLC, with progressive disease after only one prior 
chemotherapy regimen for metastatic disease. Patients with 
known EGFR mutation were allowed to receive prior oral 
epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor therapy. Eligible patients had an ECOG perfor-
mance status (PS) of 1 or less, and had adequate bone marrow, 
renal, and hepatic function. Patients were excluded if they 
had underlying condition predisposing to bleeding (history of 
nonchemotherapy-induced thrombocytopenia with bleeding 
within 1 year, active peptic ulcer, or hemorrhagic esophagitis/
gastritis, active immune thrombocytopenic purpura, etc.).
This study was conducted according to the Declaration 
of Helsinki and with approval from Institutional Review 
Boards of all participating study sites. All participants pro-
vided prior written informed consent.
Study Design
This was an open-label, randomized two arm phase 
two study of second-line therapy for metastatic nonsquamous 
NSCLC. On both arms, patients received standard-dosage on-
schedule pemetrexed (500 mg/m2 intravenously administered 
on day 1 of a 21-day cycle). Patients on arm A, also received 
200 mg itraconazole daily, starting on day 1 of cycle 1. This 
dosage of itraconazole was chosen for this initial exploratory 
study based on an expectation that this would be well toler-
ated because it reflected standard daily dosing recommenda-
tions for prolonged treatment of fungal infection. Subjects 
could remain on therapy indefinitely, until disease progres-
sion or intolerable toxicity. Although this study was not com-
pleted, the original statistical design called for a total of 112 
patients, with the intention to assess the proportion of patients 
alive and progression-free at 3 months in each arm. The null 
hypothesis based on historical controls was that 3-month PFS 
would be approximately 40%. With a target 3-month PFS of 
60%, a one-stage Fleming phase II design yielded an ɑ of 0.10 
(1-sided) and a power of 0.80 using A’Hern’s exact binomial 
probabilities.14,15
Assessments
Safety
Safety assessments included history and physical 
examinations, vital signs, ECOG PS, adverse event assess-
ment, blood chemistry, and complete blood counts with dif-
ferential. Safety assessments were performed at screening 
and at least once in each cycle of therapy, typically on day 1. 
Adverse event severity was graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0.16 All adverse effects of grade three or 
higher were tabulated, regardless of attribution to study drug. 
Relationships of adverse events to therapy (definitely, prob-
ably, possibly, unlikely, or unrelated) were assessed by the 
principal investigator.
Efficacy
Tumor response was assessed using standard Response 
Evaluation Criteria in Solid Tumors after every two cycles 
of therapy.17 The planned primary endpoint was percentage 
progression-free on each arm at 3 months. Additional 
prespecified efficacy variables included progression-free 
and overall survival assessed by Kaplan–Meier curves, with 
statistical differences assessed by log rank.
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RESULTS
Patient Characteristics and Study Drug Dosing
The study was stopped early, after a total of 23 patients 
had enrolled, because of slow accrual associated with increas-
ingly frequent use of pemetrexed as first-line and/or main-
tenance treatment of patients with metastatic nonsquamous 
NSCLC at Johns Hopkins. Fifteen patients were randomized 
to receive pemetrexed and itraconazole and eight patients to 
pemetrexed alone. The majority of patients had PS of 1. A 
summary of patient demographics is shown in Table 1. All 
patients were started at the planned dosage and schedule. The 
most common reason for study discontinuation on both arms 
was disease progression.
Safety and Tolerability
Therapy was well-tolerated on both arms, with the spec-
trum of adverse effects reflective of the known toxicities of 
pemetrexed, and disease-related complications of advanced 
lung cancer. The most common grade three toxicity on both 
arms was lymphopenia (2 of 8 on pemetrexed, and 3 of 15 on 
the combination). One patient, on the combination of peme-
trexed and itraconazole, experienced transient grade four 
neutropenia not associated with fever, and grade three leuko-
penia. Another patient on the combination arm experienced 
an intratumoral bleed in a large adrenal metastasis within the 
first 30 days after going off study; this was considered to be 
possibly therapy-related. All other grade three or higher tox-
icities were considered not or unlikely to be therapy-related, 
and are summarized in Table 2. The median number of treat-
ment cycles for patients on the combination of pemetrexed 
and itraconazole was six (range, 1–35) and the median treat-
ment duration was 4.3 months (range, 1–26) (Fig. 1). The 
median number of treatment cycles on pemetrexed alone was 
3.5 (range, 1–13) and the median treatment duration was 2.7 
months (range, 1–9).
Efficacy
Three Response Evaluation Criteria in Solid Tumors 
responses were seen, all on the combination arm (response 
rate 3 of 15 or 20%) (Fig. 1). The duration of response ranged 
from approximately 1 year to more than 2 years.
The primary objective of this study was percentage 
progression-free at 3 months, with the underlying hypothesis 
being that itraconazole administration would be associated 
with an improvement in 3-month PFS from 40% to 60%. The 
actual percentage progression-free at 3 months was 67% on 
the combination of pemetrexed and itraconazole, and 29% 
on single-agent pemetrexed. Median PFS was 5.5 months on 
the combination of pemetrexed and itraconazole versus 2.8 
TABLE 1.  Patient Demographics 
Demographic Category
Pemetrexed / 
Itraconazole 
n = 15
Pemetrexed 
n = 8
Median age (range) 60 (49–75) 59 (48–72)
Women, n (%) 7 (47) 5 (63)
ECOG PS, n (%) 0 6 (40) 4 (50)
1 8 (53) 4 (50)
2 1 (7) 0
Smoking history Never-smoker 4 (27) 3 (37)
Former smoker 11 (73%) 5 (63%)
Pack-year, median 
(range)
25 (0–80) 13 (0–70)
Driver mutationsa KRAS 3 / 11 (27%) 3 / 8 (37%)
EGFR 2 / 11 (18%) 2 / 8 (25%)
Not tested 4 0
aOne patient on arm A with CTNNB1 mutation.
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
TABLE 2.  Grade Three or Higher Adverse Events 
Toxicity
Pemetrexed / Itraconazole  
(n = 15)
Pemetrexed  
(n = 8)
Grade 3 Grade 4 Grade 3 Grade 4
Lymphopenia 3a 2a
Neutropenia 1a
Leukopenia 1a
Cough 1 1
Dyspnea 1
Pain 1
Vertigo 1
Pulmonary embolus 1
Intratumoral bleed 1a,b
aPossibly, probably, or definitely therapy-related.
bOccurred after discontinuation of study.
FIGURE 1.  Duration of therapy on study. Each vertical bar 
represents an individual patient on study. Height of the bar 
represents time on therapy, and color represents Response 
Evaluation Criteria in Solid Tumors response. PR, partial 
response; SD, stable disease; PD, progressive disease.
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months on single-agent pemetrexed (Fig. 2; hazard ratio = 
0.399, p = 0.089). Median overall survival of patients treated 
with pemetrexed on this study was 8 months; in contrast, 
median overall survival of patients treated with the combina-
tion of pemetrexed and itraconazole was 32 months (Fig. 3; 
hazard ratio = 0.194, p = 0.012).
DISCUSSION
Antiangiogenic therapy as a strategy for the treatment 
of solid tumors is attractive in many respects: tumors are 
tenuously hypoxic and highly dependent on ongoing neovas-
cularization for continued growth, and the endothelial cells 
and associated stromal elements may be more genetically sta-
ble and less likely to develop acquired resistance to targeted 
therapies than cancer cells. There have been successes in anti-
angiogenic treatment of cancer, using both targeted monoclo-
nal antibodies and small molecule receptor tyrosine kinase 
inhibitors.18 Nonetheless, the progress to date in the devel-
opment of potent and durable inhibitors of tumor-associated 
angiogenesis has not lived up to some of the initial exception-
ally high expectations.19
Most targeted antiangiogenic agents studied in cancer 
patients to date are highly selective targeted agents directed 
against key ligand-receptor interactions implicated in cancer-
associated angiogenic drive. Like these molecularly targeted 
agents, itraconazole has minimal if any cytotoxic effect on 
cancer cells directly, but has potent inhibitory activity against 
endothelial cell proliferation. Although the mechanism of 
action of itraconazole as a selective inhibitor of endothelial 
cell proliferation has not been fully defined, it seems to be a 
dirtier inhibitor, active against multiple angiogenic stimuli, in 
a variety of contexts. In multiple primary xenograft models 
of NSCLC, the efficacy of oral itraconazole in suppressing 
tumor growth was similar to that of cisplatin.11
On the basis of this promising but surprising preclinical 
data, we initiated a clinical trial to explore the efficacy of 
itraconazole in patients being treated with standard pemetrexed 
as second-line treatment for metastatic nonsquamous NSCLC. 
FIGURE 2.  Progression-free survival. Kaplan–Meier 
curves of progression-free survival by study arm are 
shown. HR, hazard ratio.
FIGURE 3.  Overall survival. Kaplan–Meier curves 
of progression-free survival by study arm are shown. 
HR, hazard ratio.
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The control arm of this study, pemetrexed alone, performed 
essentially as expected, with progression-free and overall 
survival medians of 2.8 and 8 months, respectively (compared 
with the expected 2.9 and 8.3 months based on historical 
control). In contrast, the cohort receiving the addition of 
itraconazole experienced median progression-free and overall 
survivals of 5.5 and 32 months, respectively, with the overall 
survival difference achieving statistical significance.
There are important caveats to consider in interpret-
ing these data. First, and most notably, the sample size was 
small and the estimates of effect sizes are, therefore, highly 
unstable. The study was stopped after 23 patients because of 
concerns for study feasibility: increasingly, patients with good 
PS and newly diagnosed metastatic nonsquamous NSCLC 
at our center are treated, either with a molecularly targeted 
agent (in the case of an identified driver mutation), or with a 
pemetrexed-containing doublet; this study was open only to 
patients after treatment with a prior platinum-doublet, which 
could not include pemetrexed. We are currently launching a 
second randomized phase II study of itraconazole in a more 
feasible clinical context.
Second, this initial exploratory study did not include 
correlative analyses documenting antiangiogenic effects in 
patients treated with itraconazole. Our preclinical work in 
human tumor xenograft models did convincingly demonstrate 
marked inhibition of tumor-associated vascularity, with resul-
tant tumor induction of the hypoxia-responsive gene HIF-
1α. Our upcoming trial will include serial contrast-enhanced 
magnetic resonance imaging to assess changes in tumor blood 
flow. This will be a 70-patient randomized phase II study in 
the first-line metastatic setting, evaluating a standard regimen 
of cisplatin and gemcitabine with or without itraconazole, 
with coprimary endpoints of response rate, and decrease in 
tumor-associated blood flow.
Despite these inherent limitations, the results from this 
study are entirely consistent with the strong treatment effects 
seen in our preclinical modeling of itraconazole in human 
NSCLC primary xenografts. We believe these new clinical 
data are both provocative and encouraging and should prompt 
further clinical evaluation of itraconazole as a novel therapeu-
tic for lung cancer and other solid tumors.
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TABLE 3.  Outcome Data Summary 
Outcome Measure
Pemetrexed / Itraconazole 
n = 15
Pemetrexed 
n = 8
RECIST response, n (%)
 PR 3 (20) 0
 SD 8 (53) 5 (62)
 PD 2 (13) 2 (25)
 Inevaluable 2 (13) 1 (12)
PFS
 Median (mo) 5.5 2.8
 HR (p value) 0.399 (p = 0.089)
OS
 Median (mo) 32 8
 HR (95% CI) 0.194 (p = 0.012)
RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, 
stable disease; PD, progressive disease; PFS, progression-free survival; HR, hazard ratio; 
CI, confidence interval; OS, overall survival.
